At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal worth around $10.0bn. Crinetics is a global ...

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...

Vertex Pharmaceuticals Incorporated VRTX on Monday agreed to acquire Crinetics Pharmaceuticals Inc. CRNX for $85 per share in ...

Coinbase pays us for certain activity generated through this link. Prices displayed are informational. The deal adds two assets to Vertex's portfolio. PALSONIFY is the first and only once-daily oral ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 ...